Alto Neuroscience, Inc. (NYSE: ANRO), a clinical‑stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, has announced the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of US$26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately US$100 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.
Latham & Watkins LLP is advising the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili and Orange County/Bay Area partner Ross McAloon, with associates Jie Lin Nai and Justin Deuell.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
